ArticleBlood cancer journal2025
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights.Blood advances · 2026Article
- Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.European journal of haematology · 2026Article
- Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.American journal of hematology · 2026Article
- Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- The path forward for T cell engagers in patients with prostate cancer.Journal for immunotherapy of cancer · 2026Review
- Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings.Advances in hematology · 2026Review
- European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.European journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.